AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company that discovers, designs, and develops medicines, as well as therapeutic and diagnostic products, for neurodegenerative diseases linked to protein misfolding. The company utilizes its SupraAntigen and Morphomer platforms to create biologics and small molecules that specifically interact with misfolded proteins found in various neurodegenerative diseases. Its product pipeline includes Crenezumab, a humanized, conformation-specific monoclonal antibody aimed at slowing Alzheimer's disease (AD) progression, and Semorinemab, an investigational monoclonal anti-Tau antibody designed to bind to Tau and slow its spread between neurons for AD treatment. The company is also developing ACI-24.060 for Down syndrome-related AD, ACI-7104.056 for Parkinson's disease, and ACI-35.030, which aims to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. AC Immune SA's diagnostic programs include PI-2620, a Tau diagnostic for AD and non-AD Tauopathies, and ACI-12589 and ACI-15916, which are alpha-synuclein PET tracers to aid in the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. The company is also researching Morphomer Tau aggregation inhibitors for AD, Morphomer alpha-syn to compete with small molecule inhibitors of alpha-synuclein aggregation, and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting a range of neurodegenerative diseases, including diagnostics for TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc., Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, and Eli Lilly and Company. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.